Cipla launches Cipremi, likely to price it Rs 4,000 per vial
It is looking to supply over 80,000 vials within the first month
Cipla has launched its generic version of broad-spectrum anti-viral drug remdesivir (branded Cipremi), to treat severe infection of COVID-19.
Though the company did not disclose the price of the medicine, reportedly, it is likely to be priced at Rs 4000 per vial.
Cipla had earlier said that the drug will be priced at less than Rs 5,000 per 100 mg vial.”We are proud to commercially launch Cipremi today; amongst the lowest priced globally, and aim to supply over 80,000 vials within the first month itself. To further ensure equitable distribution, the drug will be available through government and hospital channels only,” said Nikhil Chopra, Executive VP and CEO (India Business), Cipla .
“Cipla will also be donating some amount of the drug as part of its efforts to support the community in this time of need,” he added.
Hetero’s Covifor is sold at Rs 5,400 per 100 mg vial and Mylan’s Desrem is priced at Rs 4,800.
- Advertisement -
I don’t understand, what ever vaccines are developed and manufacture for corona is for treatment or for prevention. If it is for treatment, then it should be called as medicine but if it is for prevention then it should call as vaccine. By vaccine you can’t treat the patient because vaccine are designed for prevention.
Is that really? I saying that because there are many rumours about this virus and now we don’t know which is which, so now I want to know is this really good news
It is Great.
Hearty Congratulations.
Excellent social services for human mankind
Pharmaceuticals companies are taking advantage of the situation with out thinking of the country at large.
Hello Sir /madam
Can v also get vaccine.
I’m from Bangalore
As described in the article, this dose is for patients with severe covid 19 infections, and not to be seen as a vaccination. As far as I can understand, it inhibits the virus multiplication and reduces the severity of the infection. Congratulations to Cipla for timely interventions and serving humanity.